Farzane Arianfar - Department of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran
Parastoo Tarighi - Department of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran
Marjan Shariatpanahi - Department of Pharmacology and Toxicology, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran
Seyedeh Mona Mousavi Esfahani - Department of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran
Negar Mottaghi-Dastjerdi - Department of Pharmacognosy and Pharmaceutical Biotechnology, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran

Recently, the market demand for biopharmaceuticals and nutraceuticals has increased. Consequently, high-volume production strategies have also drawn a lot of attention. The invention and development of recombinant DNA technology, using various hosts from bacteria to mammalian cells, have led to the industrial-scale manufacture of many valuable pharmaceutical products. Among the hosts, yeasts have a special place due to their numerous benefits. The present study deals with commercial yeast-derived biopharmaceuticals and laboratory-scale yeast-extracted nutraceuticals. It represents the biotechnological potential of yeasts to meet the market's needs in this area. Besides, considering the COVID-۱۹ pandemic, the applications of yeast hosts for the clinical management of this disease have been briefly discussed.

Biologicals, Biopharmaceuticals, COVID-۱۹, Nutraceuticals, Yeast